Effective Treatment Of Hepatitis C

This research paper is going to review today’s silent killer, the Hepatitis C virus. This paper will talk about the description of the disease, the signs and symptoms, the etiology and risk factors, diagnostic studies, treatments and prognosis of this disease. I had lived with this disease for over ten years before diagnosed so it is important to understand the signs and symptoms so the disease can be identified and a treatment plan can be identified as the sooner it is treated the more likely it will eradicate the disease.

Hepatitis C used to affect minorities in urban areas. In June 2015, an epidemic has occurred in rural Appalachia among 18-24 year old white drug users. The sharing of needles contribute to the outbreak. In parts of Indiana, 25% of the population live in poverty, making treatment options unattainable (Galofarno

About 4.1 million people in Americans have the positive antibody for hepatitis C virus (HCV), and about 75% of them are persistently infected and most of the infections happened d 20 to 40 years ago, before the finding of HCV. Hepatitis C increased from 7,000 to 13,000 deaths in 2005. Furthermore, HCV develops slowly which increases the risk for severe complications in the infected people. Identification, death, and treatment is predicted to affect 35,000 by 2030. The Center for Disease Control (CDC) used antiviral therapy with PEGylated in clinical trials. The CDC recommends a HVC one time test for people born between 1945 and 1965.They observed testing by birth. The objective of this study was to thoroughly evaluate the amount of substance abuser infected with hepatitis C in the United States. Additional to observe the treatment of HVC. Currently Medicaid and Medicare repayment standards for sofosbuvir were calculated in all states including the District of Columbia. Medicaid and Medicare covered the drug based on the following classes liver disease stage, HIV, and drug use. Approximately 42 states reimbursed the following criteria up to 74% for the drug sofobuvir. About two thirds of the United States restricted the treatment centered on prescriber type. About 88% included drug abuse in their sofosbuvir admissibility measures. Finally 50% required a dated of abstinence and 64% required drug test. The latest drug to HVC is called Sovaldi and it costs $84,000 for the 12

There are a number of individuals who may be suffering from an illness and not even be aware they have an illness. One example of such illness is Hepatitis C (HCV). Hepatitis C is a severe disease of the liver. It is caused by the Hepatitis C virus (Centers for Disease Control and Prevention (CDC), 2015). As a result, Hepatitis C has been termed a silent epidemic (CDC, 2015). This is because a lot of individuals have Hepatitis C and don’t even realize they have the infection (CDC, 2015). As the infection begins to progress over time, it could cause acute issues to the liver (CDC, 2015). Those issues could be things like damage to the liver, the liver could fail to function, cirrhosis, or even cancer of the liver (CDC, 2015). However, screening for Hepatitis C will allow an individual to benefit from treatments that are available, hence eliminating the disease from the body and preventing the liver from undergoing any further damage (CDC, 2015).

Chronic hepatitis C virus (HCV) causes inflammation of the liver, eventually leading to tissue damage. Cirrhosis is the result of extensive scarring of the liver. The Centers for Disease Control and Prevention state that HCV typically causes cirrhosis in 5 to 20 percent of infected people over a period of 20 to 30 years. Overall, cirrhosis develops 20 to 30 percent of the time. Progression to cirrhosis may be accelerated in people who are older, obese, drink alcohol, or are immune-suppressed (such as people who are coinfected with HIV).

Purpose: The purpose of the article was to address one of the interventions in Hepatitis C treatment and the temporal aspect of it in particular. The authors use a question to begin the article which makes it easy for the reader to find the purpose of the article and later the issue which would be preceding it. Within the purpose, the authors also identify their audience being the patients living with Hepatitis C virus, the insurance companies, and the health departments. Identifying the stakeholders is effective in targeting the message to the appropriate population and further adds clarity to the issue since it would be relatable to the authors of the article as well as their audience.

This review will draw out and summarize key themes and findings from those five studies. Next, potential gaps in the research related to hepatitis C risk factors for this population will be examined. It will will then conclude with a brief discussion of future directions for research, as well as the implications of these risk factors on hepatitis C policy and interventions for urban Indigenous populations.

The disease burden is a critical issue for the decisions on the national health policies and so there is a need for accurate estimations globally, regionally and nationally. However, accurate data on the burden of chronic HCV infection are defective globally. Despite the data shortage, it was estimated that about 350,000 deaths occur each year due to HCV infections (Lavanchy, 2009).

Hepatitis C is a liver disease caused by the Hepatitis C virus. The disease can be either acute or a chronic infection, which can be mild or a lifelong disease. This disease also is the major cause of cirrhosis and liver cancer. The disease is slow moving and sometimes take up to thirty years to damage the liver. In the United States there are an estimated three to four million people with the disease and are not even aware. Approximately thirty percent of the individuals infected within six months have no symptoms and will not even be aware that they have the disease. In the remaining seventy percent infected the disease will become chronic. According to statics one hundred and seventy million people are chronically infected worldwide.

In this article, the authors identify the problem of access due to affordability of the curative and transformative therapies including the most recently found Hepatitis C therapy and a gene therapy for the highly rare disease lipoprotein lipase deficiency. The authors provide two approaches such as short-term and long-term approach that would increase the accessibility to transformative drugs. The authors suggest providing health care loans (HCL) to the consumers to help finance the expensive treatments to increase affordability. To make them affordable rapidly they provide a short-term approach which suggests financing HCLs with establishment of the special purpose entity (SPE). The SPE will be financed by a pool of investors who

Hepatitis C (HCV) is a blood borne virus that can lead to chronic liver disease and liver failure. In Canada, nearly 250,000 people have an active Hepatitis C infection (Strike, Leonard, Millson, Anstice, Berkeley, & Medd, 2006). People who inject drugs (PWID) are disproportionately represented in this statistic accounting for over 66% of those infected (Strike et al., 2006). Needle sharing among PWID is oft cited as one of the leading causes of HCV transmission (Strike et al. 2006).

“According to WebMD, 3.2 million people in the United States of America are affected by this disease. It is transmitted through bodily fluids, such as, blood, semen, saliva, sweat, and sexual contact. Additionally, it can be transmitted through the sharing of needles and drugs, unprotected sex, and it can be passed mother to baby through birth (Hepatitis C: Treatment and Care 1). People with this strand of the disease usually have no known symptoms, however, some may occur including jaundice, stomach pain, loss of appetite, Nausea, and fatigue. Treatment is from a variety of antibiotics including Daklinza, Harvoni, Technivie, and Viekira Pak. However, dangers can arise from the antibiotics Technivie and Viekira Pak causing severe liver damage. The following people should get tested for this strand of the disease; if you’ve received blood from a donor, if you’ve ever injected drugs, got a blood transfusion or organ transplant, or if you’ve ever had long term kidney dialysis (Hepatitis C: Treatment and Care

Hepatitis C is spread through direct contact with a person's infected bodily fluids, usually through a drug that needs injections and sexual activity. HCV is among the most common bloodborne infections in the United States.

One’s doctor will then conduct a physical examination to look for an enlarged and tender liver or spleen, fluid in abdomen, yellowing of skin, increased body temperature, and swollen glands in one’s neck and underarms. Generally, people infected with hepatitis C do not have symptoms, but if they do, it includes pain or bloating in the belly area, fatigue, fever, itching, joint pain, sore muscles, dark urine and pale/clay-coloured stools, jaundice, loss of appetite, nausea and vomiting, and weight loss.

Hepatitis C is an inflammation of the liver’s cells and tissues caused by the hepatitis C virus (HCV).